Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06715124 · ClinicalTrials.gov registry record · Phase 1
QTX3544 in Patients With Advanced Solid Tumors With KRAS G12V Mutations
A Phase 1 study of Advanced Solid Tumors, sponsored by Quanta Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 237
- Enrollment target
- 10
- Study locations
NCT06715124: Active Phase 1 study of Advanced Solid Tumors, sponsored by Quanta Therapeutics.
NCT06715124 is a Phase 1 study of Advanced Solid Tumors that is active but no longer recruiting, run by Quanta Therapeutics. The registered enrollment target is 237 participants, above the 197-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (20% higher). The trial reports 10 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06715124, a Phase 1 study of Advanced Solid Tumors, is active but no longer recruiting, sponsored by Quanta Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 237 participants
- Enrollment target
- 10
- Study locations
Study Summary
Phase 1 study to determine the safety, tolerability, and anti-tumor activity of QTX3544 as a single agent or in combination with cetuximab.
Primary Outcome
Define as adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug monotherapy and in combination with cetuximab.
Conditions Studied
Interventions
- COMBINATION_PRODUCT Cetuximab
- DRUG QTX3544
Study Locations (10)
Texas
- The University of Texas MD Anderson Cancer Center - Houston
- South Texas Accelerated Research Therapeutics, LLC San Antonio - San Antonio
Utah
- Huntsman Cancer Institute, University of Utah - Salt Lake City
- South Texas Accelerated Research Therapeutics Mountain Region, LLC - West Valley City
Colorado
- Sarah Cannon Research Institute - Denver
Connecticut
- Yale Cancer Center - New Haven
Florida
- Florida Cancer Specialists & Research Institute - Sarasota
Michigan
- South Texas Accelerated Research Therapeutics, LLC Midwest - Grand Rapids
North Carolina
- Duke Cancer Center - Durham
Tennessee
- Sarah Cannon Research Institute - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 237 participants |
| Start Date | 2025-01-14 |
| Est. Completion | 2029-01-02 |
| Phase | Phase 1 |
What the registry record for NCT06715124 still lists
NCT06715124 is an interventional study that assigns participants to a tested intervention. The registered 237 participants enrollment target is mid-sized for trials with a published cap, above the 197-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (20% higher).
The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 2 interventions - of which Cetuximab is the first listed.
NCT06715124 lists 10 locations in 8 states (Texas, Utah, Colorado).
Frequently Asked Questions
What is clinical trial NCT06715124 about?
NCT06715124 is a clinical study titled "QTX3544 in Patients With Advanced Solid Tumors With KRAS G12V Mutations". Phase 1 study to determine the safety, tolerability, and anti-tumor activity of QTX3544 as a single agent or in combination with cetuximab.
What is the current status of trial NCT06715124?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 237 participants. The study started on 2025-01-14. Estimated completion is 2029-01-02.
What conditions does trial NCT06715124 study?
This clinical trial studies the following conditions: Advanced Solid Tumors.
What interventions are being tested in trial NCT06715124?
The interventions under investigation include: Cetuximab (COMBINATION_PRODUCT), QTX3544 (DRUG).
Who is sponsoring clinical trial NCT06715124?
This trial is sponsored by Quanta Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06715124 being conducted?
This trial has 10 study locations across Colorado, Connecticut, Florida, Michigan, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06715124's enrollment target sits among peer trials
237 38th of 144 higher than 107 of 144 other Advanced Solid Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
RECRUITING · Phase 1
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
RECRUITING · Phase 1
-
Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
RECRUITING · Phase 1
-
SNV4818 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05974176 · 237 participants · NA
Considering Racial and Acculturation Stress in Addressing Trauma
- NCT05012072 · 238 participants · NA
Reducing Pregnancy Risks: The Mastery Lifestyle Intervention
- NCT05400252 · 238 participants · NA
Whole Health in VA Mental Health: Omnis Salutis
- NCT06380517 · 238 participants · Phase 3
Dichoptic Treatment for Amblyopia in Children 4 to 7 Years of Age
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI